|
KMID : 1040120180040010028
|
|
Evidence and Values in Healthcare
2018 Volume.4 No. 1 p.28 ~ p.37
|
|
|
Treatment patterns and Survival rates for Hepatocellular Carcinoma by Stage in South Korea
|
|
Yang Jang-Mi
Shin Sang-Jin
Choi In-Sun
|
|
|
Abstract
|
|
|
Objectives: Given the high incidence and mortality rate of hepatocellular carcinoma (HCC) in South Korea, this study aimed to investigate the difference of treatment patterns and survival rates by stage at diagnosis.
Methods: The Korean Liver Cancer Study Group (KLCSG) and the Korean Central Cancer Registry (KCCR) jointly built a nation wide cohort of patients who were diagnosed with HCC between 2008 and 2010. Using this cohort, a total of 4,596 HCC patients were analyzed for treatment status and health outcome by liver cancer stage.
Results: Mean age at the diagnosis of HCC was 59.2±11.6 years, and males comprised 77.9%. Hepatitis B was the predominant etiology (63.9%), and hepatitis C comprised 12.6%. Stage at diagnosis was 13.6%, 37.6%, 25.8%, 12.6% and 10.0% for TNM stages I, II, III, IV-A and IV-B, respectively. Initial treatment modalities were transarterial therapy in 46.3% and surgical resection in 15.8%. The 5 year survival rate by stage (I, II, III, and IV) at diagnosis were 64.5%, 54.8%, 23.5% and 4.7%, respectively. Tumor stage at diagnosis, ECOG, Child-Pugh class, age, and sex were factors independently related to survival.
Conclusion: This study confirmed that transarterial therapy is the main treatment for hepatocellular patients regardless of their tumor stage and there is a significant difference in survival outcomes according to the stage of HCC at diagnosis.
|
|
|
KEYWORD
|
|
|
Hepatocellular carcinoma, Korea, Surviva, Stage, Treatment
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|